» Articles » PMID: 36309352

Fusion of the and Genes in Uterine Leiomyoma With T(9;12)(p22;q14)

Overview
Journal In Vivo
Specialty Oncology
Date 2022 Oct 29
PMID 36309352
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aim: The translocation t(9;12) (p22;q14~15) has been reported in lipomas, pleomorphic adenomas, a myolipoma, two chondroid hamartomas, and two uterine leiomyomas. In lipomas and pleomorphic adenomas, the translocation fuses HMGA2 (12q14) with the NFIB gene from 9p22; in myolipoma, it fuses HMGA2 with C9orf92 from 9p22; and in chondroid hamartomas, fluorescence in situ hybridization (FISH) investigations showed the chromosomal aberration to cause intragenic rearrangement of HMGA2. The translocation's molecular consequence in a uterine leiomyoma is described here.

Materials And Methods: A typical leiomyoma was investigated using banding cytogenetics, FISH, RNA sequencing, reverse transcription polymerase chain reaction and Sanger sequencing.

Results: A single translocation, t(9;12)(p22;q14) leading to an HMGA2::BNC2 chimera, was found in tumor cells. A sequence of the untranslated part of exon 5 of HMGA2 (nucleotide 1035 in the NCBI reference sequence NM_003483.4) had fused with a sequence from the untranslated part of exon 7 of BNC2 from 9p22 (nucleotide 9284 in reference sequence NM_017637.6).

Conclusion: At the molecular level, the t(9;12)(p22;q14~15) found in several benign tumors appears to be heterogeneous fusing HMGA2 with either BNC2, C9orf92 or NFIB which all three map close to one another within a 3 Mbp region in 9p22. Because the fusion point in HMGA2 in the present tumor lays downstream from the first Let-7 miRNA consensus binding site, we conclude that deletion of the first Let-7 miRNA binding site is not important for the transcriptional upregulation of HMGA2 caused by the genomic rearrangement.

Citing Articles

Fusion of the High-mobility Group AT-Hook 2 () and the Gelsolin () Genes in Lipomas With t(9;12)(q33;q14) Chromosomal Translocation.

Panagopoulos I, Andersen K, Brunetti M, Gorunova L, Lund-Iversen M, Micci F In Vivo. 2023; 37(2):524-530.

PMID: 36881074 PMC: 10026638. DOI: 10.21873/invivo.13110.

References
1.
Winham S, Armasu S, Cicek M, Larson M, Cunningham J, Kalli K . Genome-wide investigation of regional blood-based DNA methylation adjusted for complete blood counts implicates BNC2 in ovarian cancer. Genet Epidemiol. 2014; 38(5):457-66. PMC: 4071957. DOI: 10.1002/gepi.21815. View

2.
Kristjansdottir K, Fogarty E, Grimson A . Systematic analysis of the Hmga2 3' UTR identifies many independent regulatory sequences and a novel interaction between distal sites. RNA. 2015; 21(7):1346-60. PMC: 4478353. DOI: 10.1261/rna.051177.115. View

3.
Nilsson M, Panagopoulos I, Mertens F, Mandahl N . Fusion of the HMGA2 and NFIB genes in lipoma. Virchows Arch. 2005; 447(5):855-8. DOI: 10.1007/s00428-005-0037-9. View

4.
Buckley M, Woods N, Tyrer J, Mendoza-Fandino G, Lawrenson K, Hazelett D . Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus. Cancer Res. 2018; 79(3):467-481. PMC: 6359979. DOI: 10.1158/0008-5472.CAN-17-3864. View

5.
Geurts J, Schoenmakers E, Roijer E, Astrom A, Stenman G, Van de Ven W . Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas. Oncogene. 1998; 16(7):865-72. DOI: 10.1038/sj.onc.1201609. View